For many MedTech companies, the first patent filing is an important milestone.
It can help protect an early invention, support investor discussions, and give the company a clearer foundation for future development. For startups especially, the first filing can also create confidence before broader commercial conversations begin.
But the first filing is not the full strategy.
If the company intends to scale, enter international markets, raise funding, build partnerships, or prepare for future acquisition discussions, patent strategy needs to look further ahead. It should reflect where the company plans to operate, what parts of the technology are commercially important, where competitors are active, and how the product may develop over time.
In medical technology, IP strategy is strongest when it supports the company’s wider product and market plans.
The first filing is only the starting point
A first patent application can be valuable, but it should not be treated as the final shape of the company’s IP position.
Medical device development rarely follows a completely linear path. The product may change as technical challenges are solved, clinical needs are clarified, regulatory strategy evolves, or user feedback is collected. Software, hardware, materials, manufacturing methods, usability, and clinical claims may all develop during the project.
If patent planning stops at the first filing, the company may later find that important product features, improvements, or commercial directions are not well covered.
This does not mean that every future development can be predicted from the beginning. It means the patent strategy should be built with enough flexibility to follow the product as it matures.
Market plans should guide patent decisions
Patent strategy should be connected to where the company expects to create value.
A filing strategy that is sufficient for one local market may not be enough for a company planning broader international expansion. If the United States is an important future market, this should be considered early. If Europe is the first commercial target, the strategy should reflect that as well. If manufacturing, licensing, distribution, or strategic partnerships may involve several regions, the patent approach should support those plans.
This is particularly relevant for MedTech companies, where EU and US market access often play an important role in the long-term business case.
The practical question is not simply where a patent can be filed. It is where protection would actually matter commercially.
For some companies, this may mean prioritising key markets early. For others, it may mean using the first filing to preserve options while the market strategy becomes clearer. In both cases, the important point is that patent decisions should be made with the company’s commercial path in mind.
EU and US strategy should be considered early
Europe and the United States are often central markets for medical device companies, but they are not identical from an IP strategy perspective.
The way claims are drafted, examined, challenged, and used commercially can differ between jurisdictions. Timelines, costs, procedural choices, and expectations around claim scope may also affect how a company should plan its portfolio.
If both regions are important, this should influence the patent strategy from an early stage.
The company should consider which parts of the invention are most commercially relevant, which future product variations may need protection, and how the patent family should support both current and future market plans.
When international planning is left too late, companies may still end up with patents in several countries, but the portfolio may not fully support the business direction.
Avoiding a fragmented portfolio
A fragmented patent portfolio can become a problem later.
This may happen when filings are made reactively, without a clear view of how the technology, product roadmap, regulatory strategy, and market plans connect. Individual applications may protect parts of the innovation, but fail to create a coherent long-term position.
For a growing MedTech company, this can become especially important during fundraising, due diligence, partnership negotiations, licensing discussions, or acquisition processes.
Investors and strategic partners often look beyond whether patents exist. They want to understand whether the IP supports the company’s product claims, competitive position, market plans, and future value.
A portfolio that has grown without a clear strategy may be harder to explain. A portfolio built around the company’s development and commercial direction is easier to connect to the wider business case.
Claim scope affects long-term value
Patent value is not only about whether a patent is granted.
A narrow patent may be easier to obtain in some situations, but if the protection does not cover the commercially important aspects of the product, its long-term value may be limited. On the other hand, broader claims need to be defensible and supported by the invention.
The goal is not to pursue broad claims for their own sake.
The goal is to protect what matters in a way that supports future defensibility, product development, and market positioning. This requires a careful understanding of the invention, the surrounding patent landscape, and the company’s commercial objectives.
Competitor analysis is an important part of this. Understanding what others have protected, where the landscape is crowded, and where there may be room to build stronger protection can help shape a more meaningful patent strategy.
Why this matters for fundraising and due diligence
For MedTech startups and scale-ups, IP strategy is often closely linked to company value.
A well-planned patent portfolio can support fundraising by showing that the company has considered not only the invention itself, but also its commercial pathway. It can help demonstrate that the company understands its competitive environment and is building protection in a way that supports future growth.
This becomes particularly important during due diligence.
Potential investors, partners, and acquirers may want to understand how the company’s IP supports its product, market strategy, regulatory pathway, and long-term defensibility. A portfolio that is strategically planned is easier to explain and easier to connect to the company’s broader value proposition.
For companies planning manufacturing scale-up, licensing, or international expansion, this clarity can make a meaningful difference.
Connecting IP strategy with product development
In MedTech, patent strategy should not sit separately from product development.
The product’s intended use, technical features, clinical value, regulatory pathway, manufacturing plans, and market strategy all influence what should be protected and where. As the product develops, the IP strategy should be reviewed and adjusted to remain aligned with the company’s direction.
This is where early and continuous planning becomes valuable.
Rather than treating patent work as a single filing event, companies can use IP strategy as a way to support better decisions throughout development. This may include assessing freedom to operate, reviewing the patent landscape, identifying commercially important features, and planning future filings around product evolution.
Building IP value beyond the first filing
A strong IP strategy does not need to be overly complex from the start.
It does, however, need to be intentional.
For MedTech companies planning EU and US markets, early patent decisions can influence future flexibility, defensibility, and commercial value. Thinking beyond the first filing helps avoid fragmented protection and supports a portfolio that grows with the product and the company.
The most useful question is not only: “Can we file a patent?”
It is also: “Does our IP strategy support where we want the company to go?”
If your team is developing a medical device and planning international growth, MDS supports companies with Freedom to Operate analysis, patent landscape review, and patent strategy aligned with product development, regulatory planning, and commercial goals.
You can contact us at sales@mdsfinland.com or via Book a Meeting.
